BARD1 Life Sciences Limited (ASX: BD1) operates in the medical line of business. The company, based in Australia, is a medical technology company which aims to develop and commercialise non-invasive diagnostic tests towards detecting an early stage cancer. It focusses on detecting the disease at primary stages and save affected lives. The company has a proprietary tumour marker platform which has the capability to focus on diagnostic and therapeutic applications through different forms of cancer.
BD1 is working towards autoantibody tests to help in detecting breast, ovarian and lung cancers in their primary stages. Moreover, diagnostic projects are in pipeline towards addressing more forms of the disease.
On 27th May 2019, BD1 announced that it had been granted with $520,518 Research and Development (R&D) Tax Incentive refund for the financial year 2017/2018. This had been provided as per the Research and Development Tax Incentive refund by the Australian Taxation Office.
The scheme helps qualified Australian companies to invest in Research and Development activities across Australia. It offers cash rebates of 43.5% towards eligible R&D expenditure. BD1 had received a “R&D Tax Incentive – Advance and Overseas Finding Certificate” on 18th February 2019, from AusIndustry. It approved its R&D activities outside Australia as well. Hence, the company was eligible for the incentive for three financial years- 2017/18, 2018/19 and 2019/20.
In 2017/18, the company spent $1,196,594 towards research and development in Australia and overseas. The funds received would be utilised to further the development and commercialisation of the company’s diagnostics pipeline activities.
Besides the Tax Incentive refund, the company had also received an Issue Notification from the United States Patent and Trademark Office, earlier in May. This confirmed the patent “Regulation of BARD1 expression by non-coding RNA”. The patent claims were directed towards siRNA that focus and lessen the expression of the novel long non-coding BARD1 RNA molecule BARD1 9?L. The patent is due to expire on 12th July 2035.
As per the company’s quarterly report for the period ending 31st March 2019, the cash flow statement provided the below mentioned details:
During the half-year ended 31st December 2018, the company raised A$3.315 million through a non-renounceable Entitlement Issue and Shortfall Offer. Its cash position was recorded at $3.7 million. The BARD1-Breast cancer test portrayed positive results with high diagnostic accuracy to detect breast cancer and the same was for Ovarian cancer too. The company bagged two patents in USA (for Ovarian and breast cancer tests) and in China (For lung cancer tests).
The company’s total comprehensible loss for the half year ended 31st December 2018 amounted to $888,038. Total assets were $3,750,025 whereas liabilities stood at $389,721. The company’s total equity was recorded at $3,360,304. BD1 generated a total revenue of $27,567.
Share Price Information:
As on 27th May 2019, the stock is trading at A$0.020 (as at AEST: 2:56 PM), up by 5.263% as compared to its previous closing price. The company’s market cap is A$18.89m. The YTD return has been -13.64%.
Disclaimer
This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice.
There is no investor left unperturbed with the ongoing trade conflicts between US-China and the devastating bushfire in Australia.
Are you wondering if the year 2020 might not have taken the right start? Dividend stocks could be the answer to that question.
As interest rates in Australia are already at record low levels, find out which dividend stocks are viewed as the most attractive investment opportunity in the current scenario in our report.
